Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q3 2025 value amounting to $301000.0.

  • Vanda Pharmaceuticals' Depreciation and Depletion rose 3935.19% to $301000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 2586.0%. This contributed to the annual value of $900000.0 for FY2024, which is 217.39% down from last year.
  • Vanda Pharmaceuticals' Depreciation and Depletion amounted to $301000.0 in Q3 2025, which was up 3935.19% from $267000.0 recorded in Q2 2025.
  • Vanda Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $374000.0 during Q4 2021, with a 5-year trough of $200000.0 in Q3 2023.
  • Its 5-year average for Depreciation and Depletion is $275578.9, with a median of $284000.0 in 2022.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Depreciation and Depletion plummeted by 3311.04% in 2023 and then soared by 3935.19% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $374000.0 in 2021, then decreased by 24.06% to $284000.0 in 2022, then fell by 27.82% to $205000.0 in 2023, then grew by 27.8% to $262000.0 in 2024, then rose by 14.89% to $301000.0 in 2025.
  • Its Depreciation and Depletion stands at $301000.0 for Q3 2025, versus $267000.0 for Q2 2025 and $231000.0 for Q1 2025.